<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060861</url>
  </required_header>
  <id_info>
    <org_study_id>Assiut19</org_study_id>
    <nct_id>NCT05060861</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy of Chadox1 Ncov-19 Vaccine: Rapid Systematic Review and Meta Analysis</brief_title>
  <official_title>Safety, Efficacy and Immunogenicity of Chadox1 Ncov-19 Vaccine: Rapid Systematic Review and Meta Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the beginning of COVID-19 pandemic, a safe and effective vaccine against infection and&#xD;
      development of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed control of the&#xD;
      wide spread of COVID-19 and reduce death rates throughout the world. Many clinical trials&#xD;
      investigated the immunogenicity of different proposed vaccine including the first distributed&#xD;
      vaccine; the ChAdOx1 nCoV-19 vaccine and there is a need to analyze the results of published&#xD;
      clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis</measure>
    <time_frame>up to one year</time_frame>
    <description>the frequency of breakthrough COVID-19 infection</description>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>ChAdOx1 nCoV-19 Vaccine</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ChAdOx1 nCoV-19 vaccine</intervention_name>
    <description>covid-19 vaccine</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants aged 18 years and older vaccinated by 2 doses of ChAdOx1 nCoV-19 vaccine&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant who received 2 doses of ChAdOx1 nCoV-19 vaccine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  non vaccinated person&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Aliae AR Mohamed-Hussein</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>September 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Aliae AR Mohamed Hussein</investigator_full_name>
    <investigator_title>Professor of Pulmonology</investigator_title>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>COVID-19 vaccine</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>upon reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

